Jack Talley

Interim CEO of the Company. He was the CEO of Izun Pharmaceuticals and previously Alissa Pharmaceuticals, a company involved in the development of radio-immunotherapy with novel targeted antibodies for hematology and solid tumors. Mr. Talley was previously the Chief Executive Officer and President at Actinium Pharmaceuticals, Inc. and President and Chief Executive Officer of EpiCept Corporation. Mr. Talley also served as the Chief Executive Officer of Consensus Pharmaceuticals and led Penwest Ltd.’s efforts in its spin-off of its subsidiary Penwest Pharmaceuticals Co. in 1998. Mr. Talley has more than 30 years of experience in the pharmaceutical industry, starting his career at Sterling Drug Inc., where he was responsible for all U.S. marketing activities and participated in the 1988 acquisition of Sterling Drug by Eastman Kodak Co. Mr. Talley completed his graduation from the Business school of New York University and undergraduation from University of Connecticut.